Rilzabrutinib LUNA 3 phase 3 study met
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study ...
Read moreRilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study ...
Read more- Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD ...
Read moreREDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to ...
Read moreRoanoke, VA, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Luna Innovations Incorporated (NASDAQ: LUNA) announced today it will report its ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.